Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

GSTM1 and Liver Iron Content in Children with Sickle Cell Anemia and Iron Overload.

Puri L, Flanagan JM, Kang G, Ding J, Bi W, McCarville BM, Loeffler RB, Tipirneni-Sajja A, Villavicencio M, Crews KR, Hillenbrand CM, Hankins JS.

J Clin Med. 2019 Nov 5;8(11). pii: E1878. doi: 10.3390/jcm8111878.

2.

Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.

Finch ER, Smith CA, Yang W, Liu Y, Kornegay NM, Panetta JC, Crews KR, Molinelli AR, Cheng C, Pei D, Ramsey LB, Karol SE, Inaba H, Sandlund JT, Metzger M, Evans WE, Jeha S, Pui CH, Relling MV.

Pediatr Blood Cancer. 2020 Jan;67(1):e28040. doi: 10.1002/pbc.28040. Epub 2019 Oct 14.

PMID:
31612640
3.

Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination.

Hoshitsuki K, Crews KR, Yang W, Smith CA, Hankins JS, Turner AJ, Broeckel U, McMillin GA, Relling MV, Haidar CE.

Genet Med. 2019 Jul 25. doi: 10.1038/s41436-019-0614-y. [Epub ahead of print] No abstract available.

PMID:
31341243
4.

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.

Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV.

J Clin Oncol. 2019 Aug 10;37(23):2051-2061. doi: 10.1200/JCO.18.02439. Epub 2019 Jun 12.

5.

Enrollee Characteristics in an Intensive Tobacco Dependence Treatment Program: The Relationship of Race and Sex to Demographic Factors and Tobacco Use Patterns.

Payne TJ, Sheffer CE, Gaughf NW, Sutton MJ, Peeples HH, Elci OU, Ma JZ, Penman A, Crews KM.

Front Psychiatry. 2019 Mar 21;10:112. doi: 10.3389/fpsyt.2019.00112. eCollection 2019.

6.

Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib.

Graetz D, Crews KR, Azzato EM, Singh RK, Raimondi S, Mason J, Valentine M, Mullighan CG, Holland A, Inaba H, Leventaki V.

Haematologica. 2019 May;104(5):e218-e221. doi: 10.3324/haematol.2018.215103. Epub 2019 Feb 28. No abstract available.

7.

In vivo measurement of trabecular meshwork stiffness in a corticosteroid-induced ocular hypertensive mouse model.

Li G, Lee C, Agrahari V, Wang K, Navarro I, Sherwood JM, Crews K, Farsiu S, Gonzalez P, Lin CW, Mitra AK, Ethier CR, Stamer WD.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1714-1722. doi: 10.1073/pnas.1814889116. Epub 2019 Jan 16.

8.

Roll-Back Eradication of Bovine Tuberculosis (TB) From Wildlife in New Zealand: Concepts, Evolving Approaches, and Progress.

Nugent G, Gormley AM, Anderson DP, Crews K.

Front Vet Sci. 2018 Nov 12;5:277. doi: 10.3389/fvets.2018.00277. eCollection 2018. Review.

9.

The Case for Pharmacogenetics-Guided Prescribing of Codeine in Children.

Gammal RS, Caudle KE, Quinn CT, Wang WC, Gaedigk A, Prows CA, Haidar CE, Taylor AK, Klein TE, Sangkuhl K, Hankins JS, Crews KR.

Clin Pharmacol Ther. 2019 Jun;105(6):1300-1302. doi: 10.1002/cpt.1260. Epub 2018 Nov 22. No abstract available.

PMID:
30467830
10.

Whole Genome Sequencing for Determining the Source of Mycobacterium bovis Infections in Livestock Herds and Wildlife in New Zealand.

Price-Carter M, Brauning R, de Lisle GW, Livingstone P, Neill M, Sinclair J, Paterson B, Atkinson G, Knowles G, Crews K, Crispell J, Kao R, Robbe-Austerman S, Stuber T, Parkhill J, Wood J, Harris S, Collins DM.

Front Vet Sci. 2018 Oct 30;5:272. doi: 10.3389/fvets.2018.00272. eCollection 2018.

11.

Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML.

Bargal SA, Rafiee R, Crews KR, Wu H, Cao X, Rubnitz JE, Ribeiro RC, Downing JR, Pounds SB, Lamba JK.

Oncotarget. 2018 Oct 9;9(79):34859-34875. doi: 10.18632/oncotarget.26163. eCollection 2018 Oct 9.

12.

Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.

Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK.

Pharmacogenomics. 2018 Sep 1;19(14):1101-1110. doi: 10.2217/pgs-2018-0086. Epub 2018 Aug 8.

13.

Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.

Quinn M, Fannin JT, Sciasci J, Bragg A, Campbell PK, Carias D, Crews KR, Gregornik D, Jeha S, Maron G, Pauley JL, Swanson HD, Wolf J, Greene W.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00173-18. doi: 10.1128/AAC.00173-18. Print 2018 Aug.

14.

Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics.

Haidar CE, Hoffman JM, Gammal RS, Relling MV, Crews KR.

Am J Health Syst Pharm. 2017 Mar 15;74(6):409-415. doi: 10.2146/ajhp160174.

15.

The impact of the UGT1A1*60 allele on bilirubin serum concentrations.

Pasternak AL, Crews KR, Caudle KE, Smith C, Pei D, Cheng C, Broeckel U, Gaur AH, Hankins J, Relling MV, Haidar CE.

Pharmacogenomics. 2017 Jan;18(1):5-16. doi: 10.2217/pgs-2016-0135. Epub 2016 Dec 14.

PMID:
27967321
16.

CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints.

Cao X, Crews KR, Downing J, Lamba J, Pounds SB.

BMC Bioinformatics. 2016 Oct 6;17(Suppl 13):382.

17.

An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.

Stock W, Diouf B, Crews KR, Pei D, Cheng C, Laumann K, Mandrekar SJ, Luger S, Advani A, Stone RM, Larson RA, Evans WE.

Clin Pharmacol Ther. 2017 Mar;101(3):391-395. doi: 10.1002/cpt.506. Epub 2016 Nov 16.

18.

Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.

Liu C, Yang W, Pei D, Cheng C, Smith C, Landier W, Hageman L, Chen Y, Yang JJ, Crews KR, Kornegay N, Karol SE, Wong FL, Jeha S, Sandlund JT, Ribeiro RC, Rubnitz JE, Metzger ML, Pui CH, Evans WE, Bhatia S, Relling MV.

Clin Pharmacol Ther. 2017 Mar;101(3):373-381. doi: 10.1002/cpt.463. Epub 2016 Nov 18.

19.

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.

Gammal RS, Crews KR, Haidar CE, Hoffman JM, Baker DK, Barker PJ, Estepp JH, Pei D, Broeckel U, Wang W, Weiss MJ, Relling MV, Hankins J.

Pediatrics. 2016 Jul;138(1). pii: e20153479. doi: 10.1542/peds.2015-3479.

20.

Comparison of genome sequencing and clinical genotyping for pharmacogenes.

Yang W, Wu G, Broeckel U, Smith CA, Turner V, Haidar CE, Wang S, Carter R, Karol SE, Neale G, Crews KR, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV.

Clin Pharmacol Ther. 2016 Oct;100(4):380-8. doi: 10.1002/cpt.411. Epub 2016 Aug 18.

21.

Shared Medical Appointments for Glycemic Management in Rural Veterans.

Crews KM, Laurenzano KR, Shorr RI.

Fed Pract. 2016 Jun;33(6):45-49.

22.

Vincristine pharmacogenomics: 'winner's curse' or a different phenotype?

Diouf B, Crews KR, Evans WE.

Pharmacogenet Genomics. 2016 Feb;26(2):51-2. doi: 10.1097/FPC.0000000000000192. No abstract available.

PMID:
26704670
23.

Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.

Scott JR, Crews KR.

Pediatr Blood Cancer. 2016 Feb;63(2):365. doi: 10.1002/pbc.25800. Epub 2015 Oct 21. No abstract available.

PMID:
26488798
24.

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2016;57(4):909-20. doi: 10.3109/10428194.2015.1086918. Epub 2015 Oct 16.

25.

NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells.

Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, Malireddi RK, Actis M, Mayasundari A, Min J, Coss DR, Laudermilk LT, Panetta JC, McCorkle JR, Fan Y, Crews KR, Stocco G, Wilkinson MR, Ferreira AM, Cheng C, Yang W, Karol SE, Fernandez CA, Diouf B, Smith C, Hicks JK, Zanut A, Giordanengo A, Crona D, Bianchi JJ, Holmfeldt L, Mullighan CG, den Boer ML, Pieters R, Jeha S, Dunwell TL, Latif F, Bhojwani D, Carroll WL, Pui CH, Myers RM, Guy RK, Kanneganti TD, Relling MV, Evans WE.

Nat Genet. 2015 Jun;47(6):607-14. doi: 10.1038/ng.3283. Epub 2015 May 4.

26.

Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy.

Crews KR, Caudle KE, Dunnenberger HM, Sadhasivam S, Skaar TC.

Clin Chem. 2015 May;61(5):775-6. doi: 10.1373/clinchem.2014.237412. Epub 2015 Mar 13. No abstract available.

27.

Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.

Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, Zheng JJ, Yang W, Fan Y, Wheeler HE, Wing C, Delaney SM, Komatsu M, Paugh SW, McCorkle JR, Lu X, Winick NJ, Carroll WL, Loh ML, Hunger SP, Devidas M, Pui CH, Dolan ME, Relling MV, Evans WE.

JAMA. 2015 Feb 24;313(8):815-23. doi: 10.1001/jama.2015.0894.

28.

Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, Molinelli AR, Stewart CF, Navid F, Jeha S, Relling MV, Crews KR.

Pediatr Blood Cancer. 2015 Sep;62(9):1518-22. doi: 10.1002/pbc.25395. Epub 2015 Jan 28.

29.

Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.

Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay N, Wong FL, Evans WE, Pui CH, Bhatia S, Relling MV.

J Clin Oncol. 2015 Apr 10;33(11):1235-42. doi: 10.1200/JCO.2014.59.4671. Epub 2015 Jan 26.

30.

Message from the editors.

Crews K, Small B.

Bioanalysis. 2015;7(1):1-4. doi: 10.4155/bio.14.315. No abstract available.

31.

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV.

Annu Rev Pharmacol Toxicol. 2015;55:89-106. doi: 10.1146/annurev-pharmtox-010814-124835. Epub 2014 Oct 2. Review.

32.

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Hicks JK, Crews KR, Flynn P, Haidar CE, Daniels CC, Yang W, Panetta JC, Pei D, Scott JR, Molinelli AR, Broeckel U, Bhojwani D, Evans WE, Relling MV.

Pharmacogenomics. 2014 Jun;15(8):1065-78. doi: 10.2217/pgs.14.53.

33.

Spotlight on medicinal chemistry education.

Pitman S, Xu YZ, Taylor P, Turner N, Coaker H, Crews K.

Future Med Chem. 2014 May;6(8):865-9. doi: 10.4155/fmc.14.51.

34.

MS imaging for cancer tissue analysis.

Crews K.

Bioanalysis. 2014 Mar;6(6):726. No abstract available.

PMID:
24829957
35.

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study.

Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews KR, Evans WE, Bostrom B, Casillas J, Dickens DS, Maloney KW, Neglia JP, Ravindranath Y, Ritchey AK, Wong FL, Relling MV.

Blood. 2014 Oct 9;124(15):2345-53. doi: 10.1182/blood-2014-01-552166. Epub 2014 May 14.

36.

PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV.

Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):45-55. doi: 10.1002/ajmg.c.31391. Epub 2014 Mar 11.

37.

The impact of brief tobacco treatment training on practice behaviours, self-efficacy and attitudes among healthcare providers.

Payne TJ, Gaughf NW, Sutton MJ, Sheffer CE, Elci OU, Cropsey KL, Taylor S, Netters T, Whitworth C, Deutsch P, Crews KM.

Int J Clin Pract. 2014 Jul;68(7):882-9. doi: 10.1111/ijcp.12386. Epub 2014 Mar 3.

PMID:
24589010
38.

Study suggests blood test can accurately detect breast cancer.

Crews K.

Bioanalysis. 2014 Feb;6(4):433. doi: 10.4155/bio.14.7. No abstract available.

39.

The seal tuberculosis agent, Mycobacterium pinnipedii, infects domestic cattle in New Zealand: epidemiologic factors and DNA strain typing.

Loeffler SH, de Lisle GW, Neill MA, Collins DM, Price-Carter M, Paterson B, Crews KB.

J Wildl Dis. 2014 Apr;50(2):180-7. doi: 10.7589/2013-09-237. Epub 2014 Jan 31.

PMID:
24484478
40.

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JA, Freimuth RR, Huser V, Lee MT, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Tyndale RF, Stein CM, Roden D, Relling MV, Williams MS, Johnson SG.

Curr Drug Metab. 2014 Feb;15(2):209-17.

41.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 Apr;95(4):376-82. doi: 10.1038/clpt.2013.254. Epub 2014 Jan 23. Review.

42.

α2δ-1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage.

Patel R, Bauer CS, Nieto-Rostro M, Margas W, Ferron L, Chaggar K, Crews K, Ramirez JD, Bennett DL, Schwartz A, Dickenson AH, Dolphin AC.

J Neurosci. 2013 Oct 16;33(42):16412-26. doi: 10.1523/JNEUROSCI.1026-13.2013.

43.

Tobacco dependence treatment: influence of training experiences on clinical activities among otolaryngologists.

Sutton MJ, Payne TJ, Gaughf NW, Crews KM, Elci OU, Peck SB, Schweinfurth J.

Laryngoscope. 2013 Dec;123(12):3005-9. doi: 10.1002/lary.23513. Epub 2013 Oct 1.

PMID:
24122575
44.

RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.

Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK.

Pharmacogenomics. 2013 Sep;14(12):1449-66. doi: 10.2217/pgs.13.131.

45.

Development and use of active clinical decision support for preemptive pharmacogenomics.

Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, Kornegay NM, Yang W, Cross SJ, Howard SC, Freimuth RR, Evans WE, Broeckel U, Relling MV, Hoffman JM.

J Am Med Inform Assoc. 2014 Feb;21(e1):e93-9. doi: 10.1136/amiajnl-2013-001993. Epub 2013 Aug 26.

46.

Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma.

Scott JR, Ward DA, Crews KR, Panetta JC, Navid F.

Pediatr Blood Cancer. 2014 Feb;61(2):373-5. doi: 10.1002/pbc.24741. Epub 2013 Aug 19.

47.

Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.

Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, Howard SC, Sandlund JT, Jeha S, Ribeiro R, Rubnitz J, Pui CH, Evans WE, Relling MV.

Cancer Chemother Pharmacol. 2013 Aug;72(2):369-78. doi: 10.1007/s00280-013-2206-x. Epub 2013 Jun 13. Erratum in: Cancer Chemother Pharmacol. 2013 Dec;72(6):1375.

48.

Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.

Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM, Pauley JL, Molinelli AR, Greene WL.

Ann Pharmacother. 2013 Jul-Aug;47(7-8):976-83. doi: 10.1345/aph.1R775. Epub 2013 Jun 4.

49.

Bridge to transplant with extracorporeal membrane oxygenation followed by HeartWare ventricular assist device in a child.

Crews KA, Kaiser SL, Walczak RJ, Jaquiss RD, Lodge AJ.

Ann Thorac Surg. 2013 May;95(5):1780-2. doi: 10.1016/j.athoracsur.2012.09.088.

PMID:
23608259
50.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.

Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group, Shuldiner AR, Vesely M, Robinson SW, Ambulos N Jr, Stass SA, Kelemen MD, Brown LA, Pollin TI, Beitelshees AL, Zhao RY, Pakyz RE, Palmer K, Alestock T, O'Neill C, Maloney K, Branham A, Sewell D, Relling MV, Crews K, Hoffman J, Cross S, Haidar C, Baker D, Hicks JK, Bell G, Greeson F, Gaur A, Reiss U, Huettel A, Cheng C, Gajjar A, Pappo A, Howard S, Hudson M, Pui CH, Jeha S, Evans WE, Broeckel U, Altman RB, Gong L, Whirl-Carrillo M, Klein TE, Sadee W, Manickam K, Sweet KM, Embi PJ, Roden D, Peterson J, Denny J, Schildcrout J, Bowton E, Pulley J, Beller M, Mitchell J, Danciu I, Price L, Pereira NL, Weinshilboum R, Wang L, Johnson JA, Nelson D, Clare-Salzler M, Elsey A, Burkley B, Langaee T, Liu F, Nessl D, Dong HJ, Lesko L, Freimuth RR, Chute CG.

Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19. No abstract available.

Supplemental Content

Support Center